Overview
Analysis
XS308180883 analysis
Key facts
H. Lundbeck A/S engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. Its product portfolio targets the following diseases: Alzheimer's, depression, Parkinson's, Schizophrenia, alcohol dependence, anxiety, bipolar disorder, epilepsy, and Huntington's. It operates through the following geographical segments: Europe, United States, and International Markets. The company was founded by Hans Lundbeck on August 14, 1915 and is headquartered in Valby, Denmark.
Go deeper with bond data
Access the most important data for bonds including coupon rates, issue ratings, redemption data and more.